VX-661 plus ivacaftor combination

DRUG2 trials

Sponsors

Vertex Pharmaceuticals Incorporated

Conditions

Cystic Fibrosis

Phase 3

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor

CompletedNCT02347657

Vertex Pharmaceuticals IncorporatedCystic Fibrosis

Start: 2015-01-31End: 2017-01-20Updated: 2018-06-12

A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation

CompletedNCT02516410

Vertex Pharmaceuticals IncorporatedCystic Fibrosis

Start: 2015-08-31End: 2016-06-07Updated: 2018-06-12

Related Papers

Development of the Cystic Fibrosis Questionnaire-Revised-8 Dimensions: Estimating Utilities From the Cystic Fibrosis Questionnaire-Revised.

2022-12-097 citations

Tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for minimal function CFTR mutations

Journal of Cystic Fibrosis2020-06-1332 citations

S69 Retrospective analysis of physiological response patterns to tezacaftor/ivacaftor in patients with cystic fibrosis homozygous for F508del-CFTR or heterozygous for f508del-CFTR and a residual function mutation

2018-11-162 citations

S68 Effects of tezacaftor/ivacaftor (TEZ/IVA) treatment in patients with cystic fibrosis homozygous for F508del-CFTR: patient-reported outcomes in a phase 3 randomized, controlled trial (EVOLVE)

2018-11-161 citations

Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del.

2017-11-03559 citations

Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del<i>CFTR</i>

New England Journal of Medicine2015-05-171603 citations